Diagnostic Utility of Procalcitonin for Sporadic Medullary Thyroid Carcinoma in Patients with Nodular Disease and Mild or Moderate Hypercalcitoninemia
Horm Metab Res 2022; 54: 220-223 DOI: 10.1055/a-1773-1127Many authors recommend the measurement of serum calcitonin (Ctn) to screen for
sporadic medullary thyroid carcinoma (MTC) in patients with thyroid nodules. In
this situation, procalcitonin (pro-Ctn) would have greater utility in patients
with hypercalcitoninemia<100 pg/ml. The aim of this
study was to evaluate the utility of pro-Ctn in patients with thyroid nodules
and without a suspicion of familial MTC or type 2 multiple endocrine neoplasia
who had mild or moderate hypercalcitoninemia without an apparent cause.
Consecutive patients with nodular thyroid disease assessed routinely by Ctn
measurement were selected. Sixty patients with basal
Ctn>10 pg/ml but<100 pg/ml were
included. Nine patients (15%) had MTC, with cytology being diagnostic in
only four. Among the 51 patients without MTC, pro-Ctn
was<0.1 ng/ml in 46 (90.2%). All patients with
MTC had pro-Ctn>0.1 ng/ml. Basal Ctn
was>24.6 pg/ml in all patients with MTC and in 42
patients (82.3%) without MTC. It is noteworthy that among patients with
basal Ctn>24.6 pg/ml (n=18)
pro-Ctn>0.1 ng/ml identified all patients with MTC and
64.2% of subjects with these pro-Ctn concentrations had this tumor. In
conclusion, we did not find superiority of pro...
Source: Hormone and Metabolic Research - Category: Endocrinology Authors: Rosario, Pedro Weslley Mour ão, Gabriela Franco Tags: Original Article: Endocrine Care Source Type: research
More News: Cancer & Oncology | Carcinoma | Cytology | Endocrinology | Hormones | Multiple Endocrine Neoplasia | Multiple Endocrine Neoplasia Syndrome | Study | Thyroid | Thyroid Cancer